Basal insulin analogues in type 1 diabetes - Does one size fit all? Lessons from the HypoDeg trial based on single-patient outcomes.

S Hjejle, R M Agesen, B Thorsteinsson, U Pedersen-Bjergaard, J M B Brøsen

Abstract read

In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

S HjejleDept. of Endocrinology and Nephrology, North Zealand University Hospital Hillerød, Dyrehavevej 29, DK-3400, Hillerød, Denmark.

R M AgesenDept. of Endocrinology and Nephrology, North Zealand University Hospital Hillerød, Dyrehavevej 29, DK-3400, Hillerød, Denmark.

B ThorsteinssonDept. of Endocrinology and Nephrology, North Zealand University Hospital Hillerød, Dyrehavevej 29, DK-3400, Hillerød, Denmark.

U Pedersen-BjergaardDept. of Endocrinology and Nephrology, North Zealand University Hospital Hillerød, Dyrehavevej 29, DK-3400, Hillerød, Denmark.

J M B BrøsenDept. of Endocrinology and Nephrology, North Zealand University Hospital Hillerød, Dyrehavevej 29, DK-3400, Hillerød, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: In the HypoDeg trial, a randomised crossover trial in people with type 1 diabetes prone to nocturnal severe hypoglycaemia, treatment with insulin degludec (IDeg) resulted in significantly reduced rates of nocturnal symptomatic hypoglycaemia and all-day severe hypoglycaemia compared to insulin glargine U100 (IGlar). We analysed HypoDeg data at a single-patient level to assess the proportion of participants to whom the overall result applied. Methods: Post hoc analysis using single-patient data (n = 133) on nocturnal symptomatic hypoglycaemia, all-day severe hypoglycaemia and HbA Results: A higher percentage (38 %) had IDeg as superior treatment compared to IGlar (15 %) for nocturnal symptomatic hypoglycaemia (p < 0.001). There was no difference between the treatments for all-day severe hypoglycaemia or HbA Conclusions: The superiority of IDeg was confirmed in many of the participants. However, a minority had IGlar as superior treatment, underscoring the need for individualised basal insulin therapy in clinical practice.

Indexed as

HypoglycaemiaIndividualised therapyInsulin analoguesInsulin degludecInsulin glargine U100Type 1 diabetes

Identifiers

PMID39624290

DOI10.1016/j.heliyon.2024.e40153

PMCPMC11609227

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.